| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLDN1 |
| Uniprot No | O95832 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-211aa |
| 氨基酸序列 | MANAGLQLLGFILAFLGWIGAIVSTALPQWRIYSYAGDNIVTAQAMYEGLWMSCVSQSTGQIQCKVFDSLLNLSSTLQATRALMVVGILLGVIAIFVATVGMKCMKCLEDDEVQKMRMAVIGGAIFLLAGLAILVATAWYGNRIVQEFYDPMTPVNARYEFGQALFTGWAAASLCLLGGALLCCSCPRKTTSYPTPRPYPKPAPSSGKDYV |
| 预测分子量 | 24.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLDN1重组蛋白的3篇参考文献示例(内容为模拟概括，实际引用请核实原文)：
1. **文献名称**：*Recombinant CLDN1 Protein Enhances Epithelial Barrier Function in vitro*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌系统表达CLDN1重组蛋白，证实其能够恢复上皮细胞模型的跨膜电阻，增强屏障功能，为肠漏症机制研究提供工具。
2. **文献名称**：*Structural Analysis of CLDN1 Recombinant Protein in Hepatitis C Virus Entry*
**作者**：Tanaka K, et al.
**摘要**：利用昆虫细胞表达系统获得高纯度CLDN1重组蛋白，通过X射线晶体学解析其胞外结构域，揭示其介导丙型肝炎病毒入侵宿主细胞的关键表位。
3. **文献名称**：*CLDN1 Recombinant Protein-Based Screening for Skin Cancer Therapeutics*
**作者**：Lee J, et al.
**摘要**：开发基于CLDN1重组蛋白的高通量药物筛选平台，发现小分子化合物可抑制CLDN1过表达黑色素瘤细胞的迁移，提示其作为治疗靶点的潜力。
如需具体文献，建议在PubMed或Web of Science中检索关键词 **"CLDN1 recombinant protein"** 并筛选近五年研究。
Claudin-1 (CLDN1) is a key transmembrane protein within the tight junction complex, critical for maintaining cell-cell adhesion and regulating paracellular permeability across epithelial and endothelial barriers. It belongs to the claudin family, comprising 27 members in humans, which form tight junction strands through homotypic or heterotypic interactions. CLDN1 consists of four transmembrane domains, two extracellular loops, and intracellular N- and C-termini. The first extracellular loop mediates paracellular barrier function, while the second influences charge selectivity.
Recombinant CLDN1 protein is engineered using expression systems like *E. coli* or mammalian cells (e.g., HEK293), often tagged with markers (e.g., His, FLAG) for purification and detection. Its production enables structural studies, antibody development, and functional assays to explore roles in physiological and pathological contexts.
CLDN1 is highly expressed in tissues such as the liver, skin, and kidney. It serves as a coreceptor for hepatitis C virus entry and is implicated in maintaining epidermal barrier integrity. Dysregulation links to diseases: overexpression associates with cancer metastasis, chemoresistance, and poor prognosis, while mutations or deficiencies cause skin disorders (e.g., ichthyosis) or leaky gut syndromes. Research leverages recombinant CLDN1 to study its interaction with pathogens, role in tumor microenvironments, and potential as a therapeutic target (e.g., monoclonal antibodies, small-molecule inhibitors). Its recombinant form also aids in developing diagnostic tools and barrier-enhancing therapies for inflammatory or infectious diseases.
×
